Skip to main content
Informational

Data use:

We use cookies and similar tools to make your use of this website easy and to keep it working properly. We may share data about you and how you use the site with third parties, such as analytics and marketing partners. Learn more in our Privacy Policy and Terms of Use. By continuing to use the site, you agree to this.

Report

Will these 4 new drugs re-shape the market?

Get the latest in this quarter’s Drug Pipeline Insights Report.

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx­ | Published: March 2022

In this latest Drug Pipeline Insights Report, Optum Rx highlights the four medications expected by the end of the second quarter of 2022. While these new drugs might be safer and more effective, they come at a cost.

The drugs in this report include treatments for:

  • A rare heart condition
  • Plaque psoriasis
  • Type 2 diabetes
  • A cardiovascular disease characterized by an abnormally thick heart muscle

Don't want to read the full report? Download the brief summary.

Related content

4 more psoriasis drugs on the way

Psoriasis costs up 40% in 5 years. Will these drugs help?

5 questions: Optum Rx chief pharmacy officer

Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.

Learn how we can help solve your challenges